Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
Abstract Some recent studies have suggested that the use of dipeptidyl peptidase-4 inhibitors (DPP4i) is associated with cancer development. However, some other studies suggest no such association. The aim of the present study was to evaluate the effect of DPP4i on the risk of developing cancers. Th...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d65c9a48207b4b24bfd98f68dab00c09 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d65c9a48207b4b24bfd98f68dab00c09 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:d65c9a48207b4b24bfd98f68dab00c092021-12-02T15:05:28ZDipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials10.1038/s41598-017-07921-22045-2322https://doaj.org/article/d65c9a48207b4b24bfd98f68dab00c092017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-07921-2https://doaj.org/toc/2045-2322Abstract Some recent studies have suggested that the use of dipeptidyl peptidase-4 inhibitors (DPP4i) is associated with cancer development. However, some other studies suggest no such association. The aim of the present study was to evaluate the effect of DPP4i on the risk of developing cancers. The electronic databases PubMed, Medline, EMBASE, Web of Science and Cochrane Library and the clinical trial registry were searched for published and unpublished randomized clinical trials on humans. Eligible studies were RCTs conducted in patients with type 2 diabetes mellitus, comparing DPP4i with a placebo or other active drugs. A total of 72 trials with 35,768 and 33,319 patients enrolled for DPP4i and the comparison drugs, respectively. Overall, no significant associations were detected between the use of DPP4i and cancer development, in comparison with the use of other active drugs or placebo. The results were consistent across pre-defined subgroups stratified by type of DPP4i, type of cancer, drug for comparison, trial duration, or baseline characteristics. The results of this meta-analysis suggest that patients with type 2 diabetes treated with DPP4i do not have a higher risk of developing cancers than patients treated with a placebo or other drugs.Ming ZhaoJiayi ChenYanyan YuanZuquan ZouXiaolong LaiDaud M RahmaniFuyan WangYang XiQin HuangShizhong BuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-14 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Ming Zhao Jiayi Chen Yanyan Yuan Zuquan Zou Xiaolong Lai Daud M Rahmani Fuyan Wang Yang Xi Qin Huang Shizhong Bu Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials |
| description |
Abstract Some recent studies have suggested that the use of dipeptidyl peptidase-4 inhibitors (DPP4i) is associated with cancer development. However, some other studies suggest no such association. The aim of the present study was to evaluate the effect of DPP4i on the risk of developing cancers. The electronic databases PubMed, Medline, EMBASE, Web of Science and Cochrane Library and the clinical trial registry were searched for published and unpublished randomized clinical trials on humans. Eligible studies were RCTs conducted in patients with type 2 diabetes mellitus, comparing DPP4i with a placebo or other active drugs. A total of 72 trials with 35,768 and 33,319 patients enrolled for DPP4i and the comparison drugs, respectively. Overall, no significant associations were detected between the use of DPP4i and cancer development, in comparison with the use of other active drugs or placebo. The results were consistent across pre-defined subgroups stratified by type of DPP4i, type of cancer, drug for comparison, trial duration, or baseline characteristics. The results of this meta-analysis suggest that patients with type 2 diabetes treated with DPP4i do not have a higher risk of developing cancers than patients treated with a placebo or other drugs. |
| format |
article |
| author |
Ming Zhao Jiayi Chen Yanyan Yuan Zuquan Zou Xiaolong Lai Daud M Rahmani Fuyan Wang Yang Xi Qin Huang Shizhong Bu |
| author_facet |
Ming Zhao Jiayi Chen Yanyan Yuan Zuquan Zou Xiaolong Lai Daud M Rahmani Fuyan Wang Yang Xi Qin Huang Shizhong Bu |
| author_sort |
Ming Zhao |
| title |
Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials |
| title_short |
Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials |
| title_full |
Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials |
| title_fullStr |
Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials |
| title_full_unstemmed |
Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials |
| title_sort |
dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials |
| publisher |
Nature Portfolio |
| publishDate |
2017 |
| url |
https://doaj.org/article/d65c9a48207b4b24bfd98f68dab00c09 |
| work_keys_str_mv |
AT mingzhao dipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT jiayichen dipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT yanyanyuan dipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT zuquanzou dipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT xiaolonglai dipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT daudmrahmani dipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT fuyanwang dipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT yangxi dipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT qinhuang dipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials AT shizhongbu dipeptidylpeptidase4inhibitorsandcancerriskinpatientswithtype2diabetesametaanalysisofrandomizedclinicaltrials |
| _version_ |
1718388859832631296 |